Search the Site


test tubes

$FRX Late-Stage Pipeline Is Key as Lexapro Patent Cliff Looms

publication date: Feb 14, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Written by Mike Havrilla--Forest Labs (NYSE:FRX) is a mid-large cap specialty pharmaceutical company that derives the majority of its revenue and profits from the sale of brand drugs (including approx. 50% of sales derived from a single product, the anti-depressant drug LEXAPRO which will lose patent protection and face generic competition beginning next month).

Sorry this page is available to subscribers only. 

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:


If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.